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Abstract
Activation of signaling dependent on the mammalian target of rapamycin (mTOR) has been demonstrated in a variety of 
human malignancies, and our previous work suggests that mTOR complex (mTORC) 1 and mTORC2 may play unique roles 
in skin tumorigenesis. The purpose of these studies was to investigate the function of mTORC2-dependent pathways in 
skin tumor development and the maintenance of established tumors. Using mice that allow spatial and temporal control 
of mTORC2 in epidermis by conditional knockout of its essential component Rictor, we studied the effect of mTORC2 loss 
on both epidermal proliferation and chemical carcinogenesis. The results demonstrate that mTORC2 is dispensable for 
both normal epidermal proliferation and the hyperproliferative response to treatment with tetradecanoyl phorbol acetate 
(TPA). In contrast, deletion of epidermal Rictor prior to initiation in DMBA/TPA chemical carcinogenesis was sufficient to 
dramatically delay tumor development and resulted in reduced tumor number and size compared with control groups. 
Silencing of Rictor expression in tumor-bearing animals triggered regression of established tumors and increased caspase-3 
cleavage without changes in proliferation. In vitro experiments demonstrate an increased sensitivity to caspase-dependent 
apoptosis in the absence of rictor, which is dependent on mTORC2 signaling. These studies demonstrate that mTORC2 
activation is essential for keratinocyte survival, and suggest that inhibition of mTORC2 has value in chemoprevention 
by eliminating carcinogen-damaged cells during the early stages of tumorigenesis, and in therapy of existing tumors by 
restricting critical pro-survival pathways.
Introduction
The mammalian (mechanistic) target of rapamycin (mTOR), 
a central regulator of cell growth that is activated by a number 
of cancer-promoting mutations in upstream signaling path-
ways, exists in at least two distinct multi-protein complexes. 
Association of mTOR kinase with Raptor defines mTOR complex 
1 (mTORC1), whereas Raptor is replaced by Rictor and mSIN1 
in mTORC2. Activation of mTORC1 controls protein synthesis 
and ribosome biogenesis by phosphorylating the key regulators 
4EBP1 and p70S6K1 (1). Although the function of mTORC2 is less 
understood, it has been shown to phosphorylate several AGC 
kinases. The best studied of these is Akt (protein kinase B), which 
promotes cell survival and proliferation when phosphorylated 
by mTORC2 at the hydrophobic motif site Ser-473 (2,3). mTORC2 
has also been implicated in control of actin cytoskeletal organiza-
tion at least in part by phosphorylation of another group of AGC 
kinases, the conventional protein kinase C isotypes (cPKCs) (4–6). 
Control of F-actin formation in fibroblasts was the first character-
ized function of mTORC2 (4,7). More recent studies in cancer cell 
lines have suggested that mTORC2 signaling alters actin cytoskel-
etal organization and cell motility in tumor invasion (8–11).
Because of their central location in cell metabolism, both 
mTOR complexes are potentially of great importance in 
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oncogenic transformation. The selective mTORC1 inhibitor 
rapamycin and its analogues are currently in clinical trials or 
have been approved as therapy against several malignancies. 
Although combination trials are more promising, the use of 
these agents as monotherapy has had limited success (12). This 
may be explained by several key findings. First, amplified Akt 
signaling has been documented in the presence of rapamycin, 
due to relief of a p70S6K1-dependent feedback loop targeting 
PI3-kinase (4,7,13,14). Loss of this feedback inhibition in some, 
though not all, cancer cells may have the effect of enhancing cell 
survival with rapamycin treatment. Also of significance was the 
observation that the initiation and progression of prostate can-
cer induced by loss of the tumor suppressor PTEN, which results 
in hyperactivation of Akt, was more effectively suppressed by 
conditional deletion of mTOR than by rapamycin treatment (15). 
This result was due to continued activity of mTORC2 in the pres-
ence of rapamycin that is eliminated when mTOR is deleted, 
and suggested that the requirement for mTORC2 activity in 
prostate tumor development is related to the activation state of 
Akt. Since aberrant activation of Akt is a feature of many tumor 
types, the possibility that mTORC2 can directly drive tumori-
genesis through this pathway must be considered. In support of 
this concept, studies have shown that the majority of gliomas 
contain high levels of p-AktS473, and both activity of mTORC2 and 
levels of Rictor were elevated in primary cells from gliomas com-
pared with cells derived from normal surrounding brain tissue 
(8). Other work suggests that Rictor confers cisplatin resistance 
to ovarian cancer cells by activating Akt (16). In the skin, mTORC2 
signaling is upregulated in human squamous cell carcinoma 
(17,18), and sustained Akt activation and increased Rictor have 
been demonstrated in mouse models of non-melanoma skin 
cancer (19–22). These findings led us to investigate whether skin 
tumorigenesis requires mTORC2-dependent signaling.
The most widely used models for the study of epithelial skin 
tumor development are the mouse models of initiation and pro-
motion. Initiation is caused by a carcinogen-induced genetic 
change in epidermal stem cells. This can be accomplished by the 
topical application of 7,12-dimethyl-benz[a]anthracene (DMBA), 
which produces a signature mutation in codon 61 of the c-Ha-ras 
gene. Tumor promotion is stimulated by multiple applications of 
an agent such as the phorbol ester 12-O-tatradecanoylphorbol-13-
acetate (TPA), which stimulates epidermal cell proliferation and 
hyperplasia (23). During promotion, initiated cells undergo clonal 
expansion, resulting in premalignant papillomas. The progression 
of papillomas to squamous cell carcinomas is strain-dependent 
and occurs stochastically; there is an increased probability of 
additional genetic alterations as the cell population expands. This 
model has been used extensively to study the effects of a variety 
of drug treatments and genetic manipulations on tumor forma-
tion and regression, including recent studies demonstrating that 
rapamycin potently inhibits tumor promotion (24).
Our previous results suggest that mTORC2 plays a critical role 
in pro-survival/anti-apoptotic signaling in keratinocytes follow-
ing exposure to the complete carcinogen ultraviolet B (UVB) irra-
diation (25). We therefore hypothesized that mTORC2-induced 
activation of pro-survival signaling contributes to skin tumori-
genesis. Here we use mouse models with stage-specific deletion 
of Rictor in the basal layer of the epidermis to extend our previous 
findings, and establish an essential role for mTORC2-controlled 
pathways in both skin tumor development and maintenance.
Materials and methods
Generation of K14-CreERT;RictorL/L mice
Floxed Rictor mice (RictorL/L) contain LoxP sites flanking exons 4 and 5 
of the rictor gene (26,27) (Figure 1A). These mice were crossed with K14-
CreERT mice (28) expressing a tamoxifen-activated Cre recombinase fused 
to a modified estrogen receptor under control of the Keratin 14 promoter 
(Jackson Labs, Bar Harbor, ME). Cre induces recombination in the outer 
root sheath of the hair follicle and the epidermal basal layer upon treat-
ment with 4-hydroxytamoxifen (4OHT; Sigma, St. Louis, MO). K14-CreERT 
mice were bred with RictorL/L mice to generate K14-CreERT;RictorL/L mice 
(Cre-RictorL/L mice), which are hemizygous for the K14-CreERT transgene 
and homozygous for the floxed rictor allele. Tail DNA was isolated using 
REDExtract-N-Amp PCR Kit (Sigma). All animals were backcrossed for 10 
generations onto the C57BL/6 background. Experiments involving mice 
were carried out in compliance with the Guide for the Care and Use of 
Laboratory Animals and protocols were approved by the Animal Care and 
Use Committee of the Pennsylvania State University College of Medicine.
Cell culture
Primary keratinocytes were isolated from 1- to 3-day old pups as described 
previously (25). Cell suspensions were plated at a density of one-half 
mouse equivalent per 60 mm2 plate, and the medium was changed every 
other day. Cultures were supplemented with 2 nM 4OHT (Sigma) [1:1000 in 
dimethyl sulfoxide (DMSO)] for 4 days to induce recombination.
Mouse embryo fibrobasts (MEFs) with constitutive deletion of ric-
tor (RictorEx3del/Ex3del) and wild-type controls (RictorEx3cond/wt), abbreviated 
Rictor−/− and Rictor+/+ (a generous gift from Dr Mark Magnuson, Vanderbilt 
University, Nashville, TN), were grown as described previously (25). MEFs 
with inducible rictor knockout (iRicKO cells) were isolated from RictorL/L 
mice, infected with a retrovirus carrying a tamoxifen-inducible Cre 
recombinase (CreERT2), and selected for stable integration of the virus (29). 
Deletion of the floxed rictor allele was induced by addition of 2 nM 4OHT to 
the culture medium daily for 3 days, and cells were exposed to UVB on day 
four. Experiments were performed when cells reached 70–80% confluence. 
Cell lines were used at passage <20 and were authenticated through veri-
fication of the wild-type or floxed rictor allele, cell morphology monitoring 
and growth curve analysis. Cells undergo routine mycoplasma contami-
nation checks and were last checked in August, 2013.
Stage-specific disruption of rictor signaling during 
two-stage carcinogenesis
Three groups of mice (control groups = Cre-RictorL/L + vehicle and RictorL/L 
+ 4OHT; experimental group = Cre-RictorL/L + 4OHT) were used at 6–8 weeks 
of age. The dorsal surface was shaved and mice were allowed to rest for 
24–48 h. Only mice in telogen (resting phase of the hair cycle) were used 
for experiments. Animals were treated topically with 2 mg 4OHT in 100 µl 
or vehicle (DMSO:Acetone [1:9]) daily for five consecutive days. Three days 
after the final 4OHT treatment, mice were initiated with a single topical 
dose of DMBA (400  nmol; Kodak Laboratory Chemicals, Rochester, NY) 
in 200 μl acetone. One week after initiation, mice began treatment with 
Abbreviations 
4OHT  4-hydroxytamoxifen 
BrdU  5-bromo-2-deoxyuridine 
CC3  Cleaved caspase-3 
DMBA  7,12-dimethyl-benz[a]anthracene 
DMSO  dimethyl sulfoxide 
FoxO  forkhead box 
H&E  hematoxylin and eosin 
i.p.  intraperitoneal 
iRicKO  inducible rictor knockout 
MEF  mouse embryo fibrobasts 
mTOR  mammalian target of rapamycin 
mTORC  mTOR complex 
PBS  phosphate-buffered saline 
PKC  protein kinase C 
TPA 12-O-tetradecanoylphorbol-13-acetate 
UVB  Ultraviolet B
T. D. Carr et al. | 489
topical TPA (17 nmol) in 200 μl acetone twice weekly for 21 weeks. Mice 
were monitored weekly for tumor formation, and the dimensions of skin 
tumors greater than 1 mm × 1 mm were recorded. Surface area was calcu-
lated as (length × width).
To analyze the effect of rictor deletion on continued growth of existing 
papillomas, Cre-RictorL/L and RictorL/L mice were subjected to two-stage skin 
carcinogenesis as described above to generate papillomas. Animals that 
developed tumors of at least 3 mm × 2 mm were treated with 2 mg of 4OHT 
(in 100 μl DMSO:sunflowerseed oil [1:9]) intraperitoneal (i.p.) for five con-
secutive days and this regimen was repeated every 2 weeks. The change in 
tumor dimensions was monitored weekly for 4 weeks. All mice continued 
to receive TPA treatment twice weekly for the remainder of the experiment.
Short-term TPA experiments
After treatment of 6- to 8-week old mice with 4OHT or vehicle for 5 days, 
17 nmol of TPA (Calbiochem-Novabiochem Corp., La Jolla, CA) in 200 μl of 
acetone was applied topically. For multiple TPA applications, mice were 
treated twice weekly for 2 weeks at 3- to 4-day interval. Mice were eutha-
nized by CO2 asphyxiation at the indicated times, and skin was fixed in 
10% neutral buffered formalin.
Histology and immunohistochemistry
For short-term TPA experiments, tissue sections were collected from mice 
48 h after the final TPA treatment. Epidermal thickness was measured in 
hematoxylin and eosin (H&E) sections at five non-overlapping locations 
for each mouse. To assess epidermal proliferation, mice received i.p. injec-
tions of 100 mg/kg 5-bromo-2-deoxyuridine (BrdU; Sigma) in saline 1 h 
prior to euthanasia. Sections were stained with an anti-BrdU antibody as 
described previously (25). Epidermal labeling index was determined by 
calculating the percentage of cells positive for BrdU. At least 100 continu-
ous basal cells were counted for each mouse at a minimum of three dif-
ferent non-overlapping locations. Apoptosis was assessed in tumors using 
immunohistochemical staining with cleaved caspase-3 (CC3) antibody 
(Cell Signaling Technology, Beverly, MA) using 3–4 mice for each condition.
UVB treatment of cells in culture
Cells were washed twice with phosphate-buffered saline (PBS), then 
in a minimal volume of PBS exposed to UVB (FS20 UVB bulbs, National 
Biological, Cleveland, OH) at doses indicated. Bulb intensity was measured 
using a UVB 500C meter (National Biological). After irradiation, PBS was 
removed and conditioned medium with drug treatments was added back. 
Mock-irradiated cells were treated identically, but without UVB exposure. 
Torin-2 (Tocris Bioscience, Minneapolis, MN), rapamycin (Developmental 
Therapeutics Program, National Cancer Institute, Bethesda, MD) or DMSO 
were added to the culture medium at a 1:1000 dilution 1 h prior to UVB. 
Cell viability was determined colorimetrically by MTS assay (CellTiter 96 
Aqueous Proliferation Assay, Promega, Madison, WI). Each condition was 
plated in triplicate and the experiments were repeated at least three times. 
Cell viability was calculated by setting the mean vehicle-treated mock UVB 
viability to 100%. Relative change in viability was calculated taking the ratio 
of cell viability of UVB to mock for each drug regimen. Where indicated, 
cells were preincubated with 50 µM Z-VAD-fmk (Cayman Chemical Co., Ann 
Arbor, MI) for 1 h prior to UVB to prevent caspase-dependent cell death.
Western blotting analysis
Cre-RictorL/L and RictorL/L mice were treated topically with 1 mg 4OHT in 
100  µl or vehicle daily for five consecutive days. Animals were eutha-
nized 14 days after the final treatment. Skin was treated with a depila-
tory agent, washed, excised and underlying fat and connective tissue 
were removed. Epidermal samples were collected by scraping the surface 
of excised skin with a razor blade and placed into ice-cold RIPA buffer 
(Santa Cruz Biotechnology, Santa Cruz, CA). Samples were sonicated, cen-
trifuged and supernatants collected. Protein concentrations were deter-
mined using the Bio-Rad reagent (Bio-Rad). Equal amounts of protein were 
subjected to electrophoresis. For in vitro studies, cells were washed twice 
with ice-cold PBS and harvested directly into sodium dodecyl sulfate sam-
ple buffer, then boiled for 2 min and stored at −20°C until use. Western 
blotting was performed as described previously (25). Antibodies used 
include Rictor, Raptor, Akt, p-AktSer473, p-AktThr308, p70S6K, p-p70S6KThr389, 
PRAS40, p-PRAS40Thr246, FoxO3a, p-FoxO1/3aThr24/Thr32, PKCα, p-PKCα/βIIThr638/
Thr641, Lamin B1, α-Tubulin (all from Cell Signaling Technology; 1:1000) and 
GAPDH (Proteintech, Chicago, IL; 1:2000).
Statistical analysis
The effect of Rictor deletion on tumor incidence was analyzed using 
log-rank analysis of Kaplan-Meier tumor-free survival curves. For tumor 
Figure 1. 4OHT induces LoxP recombination and Rictor deletion in epidermis and primary keratinocytes of Cre-RictorL/L mice. (A) Schematic representation of the rictor 
allele targeted for K14-Cre-mediated recombination. (B) 7-week old Cre-RictorL/L mice were treated topically with 2-mg 4OHT or vehicle daily for 5 days. Top, PCR analy-
sis of epidermal DNA harvested 7 days after final 4OHT treatment. ∆LoxP denotes primers specific to the recombined rictor allele. Bottom, immunoblot analysis of Raptor 
and Rictor in epidermal extracts harvested 7 days after final 4OHT treatment. Data are representative of two experiments. (C) Cre-RictorL/L and RictorL/L keratinocytes 
were harvested from 1–3 day-old pups and cultured in 4OHT (2 nM) or vehicle for 3 days. Top, PCR analysis of primary keratinocyte DNA harvested 24 h after final 4OHT 
treatment. ∆LoxP denotes primers specific to the recombined Rictor allele. Bottom, immunoblot analysis of Rictor in primary keratinocyte whole-cell lysates. Data are 
representative of 2–3 independent experiments.
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multiplicity, differences in the average number of papillomas per mouse 
were analyzed using 2-way analysis of variance. Tumors were counted 
only if the length and width were both greater than 1 mm. Tumors in 
regression experiments were compared with their initial size using a two-
tailed paired student’s t-test. All other statistical comparisons utilized a 
two-tailed unpaired Student’s t-test.
Results
Characterization of LoxP recombination and rictor 
deletion in Cre-RictorL/L epidermis and primary 
keratinocytes
The early embryonic lethality caused by deletion of the ric-
tor gene (30) led us to use a 4OHT-inducible Cre-LoxP system 
to selectively ablate rictor in mouse epidermal basal cells in 
order to investigate the role of mTORC2 in skin tumorigenesis. 
To validate the efficiency of rictor deletion in the epidermis of 
Cre-RictorL/L mice, we used topical treatment of 4OHT or vehi-
cle daily for 5  days. PCR analysis using DNA from the dorsal 
epidermis harvested from mice 1 week after the final 4OHT 
treatment verified that recombination occurred only in mice 
expressing the K14-CreERT transgene and treated with 4OHT 
(Figure  1B). Immunoblot analysis of epidermal extracts con-
firmed reduced levels of Rictor in mice treated with 4OHT, but 
not vehicle-treated mice, and levels of Raptor were unchanged 
(Figure 1B). PCR and western blot analysis of primary keratino-
cytes isolated from Cre-RictorL/L mice also verified recombina-
tion of the rictor allele (∆LoxP) and rictor deletion in cells cultured 
with 4OHT, but not vehicle (Figure  1C). Western blots of Cre-
RictorL/L primary keratinocytes treated with 4OHT indicated 
Rictor and p-AktSer473 were below the limit of detection, whereas 
Raptor was unchanged (Figure 1C).
Measurement of normal keratinocyte proliferation in 
the presence of epidermal rictor deletion
To examine whether absence of epidermal Rictor results in 
defective keratinocyte proliferation, we analyzed the epidermis 
of Cre-RictorL/L mice. H&E staining of paraffin-embedded sec-
tions showed that untreated epidermis was normal in struc-
ture of both follicular and interfollicular epidermis (Figure 2A). 
Application of 4OHT to induce recombination and rictor dele-
tion caused no apparent change in morphology or in epidermal 
thickness (Figure 2A and B). When epidermal proliferation was 
analyzed by BrdU incorporation as a marker of DNA synthesis, 
labeling was almost absent in untreated epidermis, whereas 
topical application of 4OHT resulted in a moderate increase 
(Figure 2C and D). Although the reason for this increase is not 
known, no mice were found to develop skin abnormalities over 
Figure. 2. Effect of rictor deletion on basal and TPA-stimulated epidermal proliferation. Cre-RictorL/L mice at 7–8 weeks of age were treated topically with 4OHT (2 mg) or 
vehicle (D:A) daily for 5 days. A subset of mice from each group were then treated with either 17 nmol TPA or DMSO four times over a 2-week period. Mice were killed 6 h 
after the final TPA treatment. (A) Representative H&E images of skin sections (scale bar = 50 µm). (B) Quantitation of epidermal thickness (mean ± SEM) for n = 4 mice/
group; ***P < 0.0001 for Cre-RictorL/L TPA compared with Cre-RictorL/L D:A; ***P < 0.0001 for Cre-RictorL/L 4OHT+TPA compared with Cre-RictorL/L 4OHT. (C) Representative 
BrdU incorporation of mice injected with 100 mg/kg BrdU 1 h before killing (scale bar = 50 µm). (D) Quantitation of BrdU labeling index (mean ± SEM) for n = 4 mice/group; 
**P < 0.005 for Cre-RictorL/L 4OHT compared with Cre-RictorL/L D:A; **P < 0.005 for Cre-RictorL/L TPA compared with Cre-RictorL/L D:A; *P < 0.05 for Cre-RictorL/L) 4OHT + TPA 
compared with Cre-RictorL/L 4OHT. There is no statistical difference between Cre-RictorL/L TPA and Cre-RictorL/L 4OHT + TPA groups (P = 0.3819).
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time following Rictor recombination, and mice have a normal 
life span (data not shown).
It has been shown previously that rapamycin has a dramatic 
inhibitory effect on TPA-induced epidermal hyperproliferation 
(24). Because prolonged exposure to rapamycin can also inhibit 
mTORC2 activity in some cancer models (31,32), we exposed 
mice with epidermal-specific rictor deletion to multiple appli-
cations of TPA to determine the role of mTORC2 in the TPA 
response. In contrast to the results reported with mTORC1 inhi-
bition, loss of Rictor had no effect on epidermal hyperprolifera-
tion either by visual inspection (Figure 2A and C) or quantitative 
analysis (Figure 2B and D). Epidermal thickness of Cre-RictorL/L 
mice treated with TPA alone was significantly greater than both 
vehicle- and 4OHT-treated mice, and the combination of 4OHT 
+ TPA had no additional effect (Figure 2B). Similarly, BrdU incor-
poration was indistinguishable in mice treated with TPA alone 
compared with mice treated with 4OHT + TPA (Figure  2D). As 
mentioned above, addition of 4OHT alone increased the labe-
ling index moderately compared with vehicle-treated mice, but 
epidermal BrdU incorporation in Cre-RictorL/L mice + 4OHT was 
only about 50% of Cre-RictorL/L mice treated with either TPA or 
with 4OHT + TPA (Figure 2D).
Rictor is necessary for skin tumorigenesis
To determine the role of Rictor during the initiation stage of skin 
carcinogenesis, mice were treated with 4OHT prior to initiation 
with a single topical dose of DMBA. One week later, mice were 
treated topically with TPA twice weekly for 21 weeks (Figure 3A). 
Using this protocol, we found that Cre-RictorL/L mice are remark-
ably resistant to tumorigenesis. At the end of 21 weeks, there 
was a striking reduction in tumor incidence from 100% in both 
control groups to only 38% in the inducible Rictor-deficient mice 
(P  <  0.0001, Figure  3B). In addition, Cre-RictorL/L mice treated 
with 4OHT showed a delay in tumor development relative to 
the control groups, and the average number of papillomas per 
mouse was significantly lower from week nine until the end of 
the experiment (P < 0.005, Figure 3C). Rictor ablation in the basal 
epidermis also led to a dramatically lower tumor burden, with 
the average surface area of tumors in Cre-RictorL/L mice + 4OHT 
reduced at least 90% compared with both control groups at the 
end of the experiment (P  <  0.005, Figure  3D). Taken together 
with the results above, these data show that loss of Rictor in the 
basal cells of the epidermis attenuates tumor initiation without 
affecting proliferation of normal keratinocytes.
Figure 3. Effect of rictor deletion on two-stage skin carcinogenesis and tumor regression. Rictor-deficient mice [Cre-RictorL/L + 4OHT n = 16] and two control groups [Cre-
RictorL/L + DMSO n = 17, RictorL/L + 4OHT n = 17] were subjected to a two-stage skin carcinogenesis protocol. Papillomas greater than 1 mm × 1 mm were counted weekly. 
(A) Protocol used to examine the effect of rictor deletion on tumor development and maintenance. Top, for carcinogenesis experiments, rictor deletion was induced 
prior to 200 nmol DMBA initiation with topical application of 4OHT daily for five treatments. One week after DMBA initiation, mice received twice-weekly applications 
of 17 nmol TPA until the end of the experiment. Bottom, for tumor regression experiments, when tumors reached a minimum size of 3 mm × 2 mm, rictor deletion was 
induced with i.p. injections of 4OHT repeated daily for 5 days, and the regimen was repeated every 2 weeks. Twice weekly TPA treatments were continued and tumors 
were harvested 4 weeks after the initial 4OHT treatment. (B–D) Effect of rictor deletion prior to initiation on tumorigenesis. (B) Percentage of mice with papillomas. (C) 
Average number of tumors per mouse; mean ± SEM. (D) Average surface area of tumors per group; mean ± SEM.
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Deletion of rictor in existing papillomas causes 
tumor regression
Previous results have demonstrated that treatment of tumor-
bearing mice with rapamycin rapidly decreased tumor burden 
(24,33). To evaluate whether rictor deletion and mTORC2 inhi-
bition in pre-existing papillomas blocked continued growth, 
a separate cohort of Cre-RictorL/L and RictorL/L mice were first 
subjected to two-stage skin carcinogenesis to generate papil-
lomas, then treated with multiple i.p. injections of 4OHT over 
a 2-week period (Figure 3A). All mice continued to receive TPA 
treatment twice weekly for the remainder of the experiment. 
The results demonstrate that 4OHT-induced rictor disruption 
in tumors inhibited their further growth (Figure  4). Among 
the 12 tumors from Cre-RictorL/L mice treated with 4OHT, 10 
underwent a reduction in tumor size, whereas all tumors from 
identically-treated RictorL/L mice either increased in size or 
remained constant (Figure 4A, Supplementary Table 1, available 
at Carcinogenesis Online). Additionally, the relative size of tumors 
in Cre-RictorL/L mice was significantly smaller than in the control 
group (P < 0.01 at week four). Although the average tumor size 
in control mice increased significantly by the conclusion of the 
experiment (P < 0.05 relative to initial size), the surface area of 
tumors from inducible Rictor-deficient mice decreased signifi-
cantly (P < 0.05) (Figure 4B). These results clearly indicate that 
inducible disruption of rictor in established tumors leads to their 
regression.
To determine the mechanism of tumor regression in 
response to rictor deletion, mice were killed 4 weeks after the 
beginning of the regression experiment (week 25 of the carcino-
genesis experiment), and serial sections from paraffin-embed-
ded tumors were analyzed. Examination of H&E sections from 
each genotype determined that all tumors (12 tumors from 
Cre-RictorL/L mice and 8 tumors from RictorL/L mice) were well-
differentiated papillomas (Figure 4C). To establish whether loss 
of Rictor decreases tumor cell proliferation, mice were injected 
with BrdU and tumors were analyzed for S-phase cells. Although 
Figure 4. Effect of rictor deletion in established tumors. Cre-RictorL/L and RictorL/L mice were subjected to two-stage skin carcinogenesis as described in Figure 3 to gener-
ate papillomas. When tumor size reached at least 3 mm × 2 mm, mice were treated with 2 mg of 4OHT (in 100 μl DMSO:sunflowerseed oil [1:9]) i.p. for five consecutive 
days and this regimen was repeated every 2 weeks. Dimensions of tumors were measured prior to 4OHT treatment and weekly thereafter. Mice continued to receive 
TPA twice weekly. A total of 12 tumors were monitored in Cre-RictorL/L mice (Cre/Ric; n = 7 mice), and 8 tumors were monitored in RictorL/L mice (Ric; n = 5 mice). (A) 
Waterfall graph showing the percent change in surface area for each individual tumor relative to its initial size. One tumor from the RictorL/L group did not change in 
surface area over the 4 weeks. One tumor from the RictorL/L group increased in size by 700% and was not included. (B) Average percent change in surface area relative 
to initial size; mean ± SEM. * = significantly different from RictorL/L mice (P < 0.05). (C) Histological analysis of tumors from Cre-RictorL/L and RictorL/L mice 4 weeks after 
4OHT treatment. Left, typical keratinocyte-derived exophytic lesions of the skin in both experimental groups. Middle, mice were injected with BrdU (100 mg/kg, i.p.) 1 h 
before killing and proliferating cells were stained with an anti-BrdU antibody as described in the Materials and Methods. Results are representative of all tumors taken 
from 7 Cre-RictorL/L and 5 RictorL/L mice. Right, tumors were analyzed for expression of CC3 as described in the Materials and Methods. Results are representative of mul-
tiple tumors taken from 3–4 mice in each group. (D) Quantitation of BrdU and CC3 results in C. Total positive cells in four non-overlapping fields were counted for each 
tumor. Five tumors from each genotype were quantitated, and results are expressed as mean ± SEM, shown as line with error bars. CC3-positive cells are significantly 
different between the two groups, P < 0.01. BrdU incorporation was not different between the groups.
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tumors from 4OHT-injected Cre-RictorL/L mice were strikingly 
smaller than those from RictorL/L mice treated in the same 
way (Figure 3D), tumors from both groups demonstrate similar 
incorporation of BrdU (Figure 4C and D). This is consistent with 
the unaltered hyperproliferation response observed in the skin 
of Rictor-deficient mice after TPA treatment (Figure 2). In con-
trast, regressing tumors from Cre-RictorL/L mice show patches of 
strong staining for CC3 whereas significantly less CC3 staining 
is observed in tumors isolated from RictorL/L mice (Figure 4C and 
D), suggesting that Rictor loss sensitizes tumors to apoptosis 
and subsequent regression even in the continued presence of a 
promoting stimulus.
Increased sensitivity to UVB-induced apoptosis upon 
rictor deletion in vitro is dependent on mTORC2
The results in Figure  4 are consistent with increased apopto-
sis in DMBA/TPA-induced tumors upon rictor ablation. We have 
also shown previously that Rictor−/− MEFs were sensitized to 
UVB-induced apoptosis (25). To directly address the question of 
whether increased cell death in the absence of Rictor is depend-
ent on mTORC2, we used wild-type and rictor-null MEFs exposed 
to UVB and treated with either the TOR kinase inhibitor Torin-2 
or the mTORC1 inhibitor rapamycin (Figure 5). We first tested the 
ability of rapamycin or Torin-2 to inhibit UVB-induced activation 
of mTOR signaling. Western blot analysis showed that in wild-
type cells both Torin-2 and rapamycin completely blocked UVB-
induced phosphorylation of p70S6K1T389, a marker of mTORC1 
activity. Torin-2 also reduced phosphorylation of Akt at the 
mTORC2 site S473, whereas rapamycin had no effect (Figure 5A). 
In Rictor−/− cells, both inhibitors prevented UVB activation of 
mTORC1 signaling, whereas Akt phosphorylation at Ser-473 was 
not measurable. Although Torin-2 increased UVB-mediated cell 
death in wild-type cells compared with treatment with either 
rapamycin or vehicle control, it did not have a similar effect in 
Rictor−/− cells (Figure 5B), suggesting that the increased cell death 
in Rictor−/− cells is dependent on mTORC2 signaling. Western 
blots indicated increased caspase-3 cleavage of wild-type cells 
exposed to Torin-2, but not of Rictor−/− cells (Figure 5C). In addi-
tion, pre-incubation with the pan-caspase inhibitor Z-VAD-fmk 
significantly suppressed UVB-induced cell death in iRicKO cells 
in which rictor deletion was induced by treatment with 4OHT 
(Figure 5D). Taken together, these results demonstrate that loss 
of Rictor sensitizes cells exposed to UVB in vitro to caspase-
dependent apoptosis. We further elucidated the role of mTORC2 
in genotoxic stress by exposing iRicKO cells with and without 
rictor deletion to cisplatin, then performing clonogenic assays. 
Like exposure to UVB, increased cisplatin-induced cytotoxicity 
is observed in the absence of Rictor (Supplementary Figure 1A 
and B is available at Carcinogenesis Online).
To further explore the potential biochemical mechanisms 
by which Rictor loss can sensitize cells to apoptosis, we exam-
ined activation of both mTORC1 and mTORC2 downstream 
effectors in iRicKO cells over a time course of 24 h post-UVB. 
UVB exposure led to a rapid, time-dependent phosphorylation 
of both p70S6K1T389 and AktS473 in cells with wild-type levels of 
Rictor (+ vehicle; Figure 6, Supplementary Figure 2, available at 
Carcinogenesis Online), indicating activation of both mTORC1- 
and mTORC2-dependent pathways. Treatment with 4OHT to 
induce rictor recombination had little inhibitory effect on phos-
phorylation of the mTORC1 downstream effectors p70S6K1T389 
and PRAS40T246 (Figure  6A). Total p70S6K1 and PRAS40 were 
also unchanged. The exception was at the 24-h time point, 
when significant cell toxicity was observed (data not shown). 
Interestingly, the phosphorylation of AktT308 in response to 
UVB was increased slightly in the absence of Rictor (Figure 6A, 
Supplementary Figure 2A, available at Carcinogenesis Online).
In contrast to mTORC1 pathway intermediates, the robust 
UVB-dependent phosphorylation of AKTS473 observed in vehi-
cle-treated cells was almost completely lost in cells with 
4OHT-induced rictor recombination (Figure  6B, Supplementary 
Figure  2B, available at Carcinogenesis Online). This marked 
reduction in UVB-induced AktS473 phosphorylation suggests 
that mTORC2 is the primary kinase that phosphorylates Akt 
in response to UVB, rather than the DNA-dependent protein 
kinase, a PIKK family kinase reported to phosphorylate Akt at 
Ser-473 in response to gamma irradiation (34). UVB-stimulated 
phosphorylation of forkhead box (FoxO) transcription factors 
1/3a at Thr-24/32, which are targets of p-AktS473 (1), was rapidly 
reduced in cells treated with 4OHT. This is particularly true 
for FoxO3a (top band in p-FoxO1/3a blot, Figure  6B), and was 
accompanied by a decrease in total FoxO3a with time after UVB 
(Figure 6B, Supplementary Figure 2B, available at Carcinogenesis 
Online). Since phosphorylation of FoxO1/3a by Akt is inhibitory 
to FoxO-dependent transcription of pro-apoptotic genes, these 
results suggest that, in Rictor-depleted cells, FoxO-dependent 
signaling is activated over several hours in response to UVB. 
Phosphorylation of PKCα/βII at Thr-638/641, whereas not signifi-
cantly changed by UVB exposure, was decreased by about 40% 
in cells treated with 4OHT (Figure 6B, Supplementary Figure 2B, 
available at Carcinogenesis Online). This PKCα/βII phosphoryla-
tion site has been reported to require mTORC2 (5,6), and mTORC2 
is also implicated in PKC stability (35). In agreement with this, 
total PKCα was also decreased in cells with Rictor disruption 
(Figure 6B, Supplementary Figure 2B, available at Carcinogenesis 
Online).
Discussion
In this study, we determined the role of the essential mTORC2 
component Rictor during two-stage DMBA/TPA carcinogenesis 
in mouse skin. Using a Cre/LoxP approach to enable both spatial 
and temporal control of gene deletion, we found that absence 
of Rictor in the hair follicle and basal layer of the epidermis had 
no effect on normal epidermis stimulated to proliferate by mul-
tiple applications of TPA. In contrast, when rictor was ablated 
prior to initiation, mice were markedly more resistant to DMBA/
TPA-induced tumor development than controls. Silencing of 
Rictor expression in tumor-bearing animals triggered regres-
sion of established tumors accompanied by increased levels 
of apoptosis without changes in proliferation. In vitro studies 
suggest the increased sensitivity to apoptosis in the absence 
of Rictor is mediated through mTORC2-dependent control of 
p-AktSer473 signaling without alterations in pathways controlled 
by mTORC1. These data provide strong evidence that mTORC2 
is necessary for both skin tumor development and maintenance 
of established tumors.
Previous work has established that Rictor plays an essential 
role in the developing embryo (3), whereas conditional deletion 
of rictor in adipose tissue, liver and brain revealed the functional 
importance of mTORC2 in these organs (27,36,37). To investi-
gate the contribution of mTORC2 to normal epidermal homeo-
stasis and skin carcinogenesis, we used a model in which rictor 
recombination is driven by the Keratin 14 promoter in a 4OHT 
inducible manner, resulting in loss of rictor in the basal layer of 
the epidermis. We first showed that rictor deletion in adult epi-
dermis caused no apparent defects in skin architecture and did 
not alter the proliferation response to multiple applications of 
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TPA, despite a dramatic reduction in epidermal p-AktS473. This is 
consistent with previous studies in Drosophila, where loss of Akt 
hydrophobic motif phosphorylation had little effect on normal 
tissue growth (38). Similarly, Rictor-dependent phosphorylation 
of AktS473 was shown to be non-essential in mouse skeletal mus-
cle and normal prostate epithelium (26,39). Akt is both upstream 
of mTORC1 and downstream of mTORC2, and dual phosphoryla-
tion of Akt at Ser473 by mTORC2 and Thr308 by PDK1, which is 
a component of the PI3-kinase signaling cascade, is required for 
complete activation (1). Because the absence of p-AktS473 affects 
only a subset of Akt targets (40), our results suggest that normal 
epidermal proliferation is dependent on substrates of p-AktT308, 
and consequently requires mTORC1. Although signaling inter-
mediates other than Akt are also involved in epidermal pro-
liferation, our findings are in agreement with previous results 
showing that rapamycin potently inhibits TPA-induced epider-
mal hyperproliferation (24), and that overexpression of a consti-
tutively activated form of Akt in the skin causes a hyperplastic 
epidermal phenotype (21).
Using a chemical carcinogenesis protocol, we went on to 
investigate the effect of rictor ablation on skin tumor develop-
ment. Our previous studies suggest that mTORC2-dependent 
pathways control keratinocyte survival signaling in response to 
DNA damage (25). We therefore took advantage of the inducible 
nature of the K14-CreERT transgene to direct rictor recombina-
tion prior to DMBA initiation. Rictor deficiency in the skin dra-
matically delayed tumor development compared with both 
control groups, and tumors from 4OHT-treated Cre-RictorL/L 
mice averaged over 90% fewer in number and smaller in size. 
Thus, mTORC2 is necessary for skin tumor initiation, but not 
for keratinocyte proliferation. Our results fit with those dem-
onstrating that mTORC2 is required for prostate tumor devel-
opment in PTEN−/− mice (15,39), and also reinforce previous 
observations of aberrant Akt activation in mouse models of 
non-melanoma skin cancer (19,21). Taken together, these data 
support the hypothesis that mTORC2 is essential to maintain 
high Akt signaling in these tumor types. PCR analysis of tumors 
from Cre-RictorL/L mice treated with 4OHT revealed the presence 
of the recombined rictor allele in 4 of 6 tumors (data not shown). 
However, this does not rule out the possibility that these tumors 
arose from initiated cells that escaped recombination.
An equally important and novel finding in our study is that 
disruption of rictor after tumors had formed not only prevented 
further growth, but also led to tumor regression. Furthermore, 
this regression occurs without changes in proliferation but with 
increased cleavage of caspase-3, consistent with increased apop-
tosis. These results suggest that mTORC2 plays a critical role in 
mediating keratinocyte survival pathways, and identify mTORC2 
Figure 5. Effect of rapamycin or Torin-2 treatment of wild-type and Rictor-deficient cells on UVB-induced cell death. (A–C) Rictor wild-type (+/+) and knock-out (−/−) 
MEFs were treated with rapamycin (50 nM), various doses of Torin-2 (nM) or DMSO for 1 h prior to UVB (20 mJ/cm2). (A) Whole cell lysates were harvested in RIPA buffer 
at 2 h post-UVB and subjected to immunoblot analysis of mTORC1 and mTORC2 activation markers. (B) MTS cell viability at 12 h post-UVB exposure showing % change 
in viability with UVB; *P < 0.05. (C) Immunoblot analysis of CC3, at 12-h post-UVB. Data are representative of 2–3 independent experiments. (D) iRicKO cells were treated 
with either vehicle or with 4OHT for 3 days to induce rictor recombination, as described in the Materials and Methods. On day four, cells were pre-incubated with DMSO 
or 50 µM Z-VAD-fmk for 1 h, then exposed to 50 mJ/cm2 UVB or mock-irradiated. Cells were harvested 24 h later and cell viability was measured by MTS assay. Data 
are representative of 2 independent experiments.
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as a target for both prevention and treatment of non-melanoma 
skin cancer. Furthermore, since cutaneous squamous cell carci-
noma often becomes resistant to standard cisplatin therapy (41), 
our clonogenic data support the study of TORC2 inhibitors as a 
therapeutic option in the setting of cisplatin resistance.
As an extension of our in vivo studies, we demonstrated 
that cells with loss of rictor are sensitized to caspase-depend-
ent apoptosis in response to carcinogen exposure in vitro. 
Further, we observed reduced p-AktSer473 in rictor-deficient pri-
mary keratinocytes and MEFs. It is known that mTORC2 phos-
phorylation of Akt at Ser-473 promotes cell survival through a 
number of downstream effectors (2–6,42). Whereas dual phos-
phorylation of Akt at Thr-308 and Ser-473 is necessary for its 
full activation, Ser-473 phosphorylation alone is sufficient for 
Akt to inhibit FoxO1/3a transcription factors by phosphorylating 
multiple residues that cause sequestration of FoxO in the cyto-
plasm (40). When p-AktS473 is inhibited, unphosphorylated FoxO 
translocates to the nucleus and activates transcription of apop-
tosis effectors such as FasL, TRAIL and the Bcl-2 homology 
domain (BH3)-only proteins (43,44). Our results show a selective 
reduction in p-AktS473 without reduced p-AktT308 in 4OHT-treated 
iRicKO cells exposed to UVB. FoxO1/3a phosphorylation at the 
Akt target site Thr-24/32 is decreased in these cells, consistent 
with FoxO1/3a activation when cells that lack Rictor are sub-
jected to a carcinogenic stimulus.
Rictor has been reported to act independently of mTORC2 
through functional interactions with a number of proteins. 
Protein complexes of Rictor with PKCζ, Myo1C, and inhibitor of 
nuclear factor κ-B kinase (IKK) are all associated with changes 
in actin cytoskeletal organization (45–47). The Rictor-Cullin 1 
Figure 6. Biochemical analysis of mTORC1- and mTORC2-dependent signaling in response to UVB. iRicKO cells were treated with vehicle or with 4OHT for 3 days to 
induce rictor recombination. On day four, cells were exposed to 20 mJ/cm2 UVB, and harvested in 1× sodium dodecyl sulfate sample buffer at the indicated time points 
for immunoblot analysis. For each protein analyzed, samples from both treatment groups are loaded onto the same gel to allow direct comparison of protein expression 
levels. (A) Expression of mTORC1 signaling intermediates over a time course from T = 0 to T = 24 h after UVB exposure. (B) Expression of mTORC2 signaling intermedi-
ates over the same time course. Quantitation of blots is shown in Supplementary Figures 1A and B is available at Carcinogenesis Online. Phosphorylated proteins were 
normalized to their corresponding total protein on the same gel and other proteins were normalized to either Lamin B1 or Tubulin on the same gel, as described in 
the legend for Supplementary Figure 2, available at Carcinogenesis Online. One Lamin B1 blot and one Tubulin blot are shown for reference. Results are representative 
of 2–3 independent experiments.
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complex acts as an E3 ubiquitin ligase to control degradation of 
the serum and glucocorticoid-inducible kinase (48). Serum and 
glucocorticoid-inducible kinase, like Akt, is an AGC kinase that 
can phosphorylate FoxO1/3a (49). However, unlike Akt, which 
is negatively regulated by loss of Rictor, serum and glucocorti-
coid-inducible kinase is induced in Rictor−/− MEFs as a result of 
increased protein stability (48). Since we see reduced FoxO phos-
phorylation in UVB-treated iRicKO cells, this suggests that Akt 
signaling is dominant in our system. It has also been found that a 
complex between Rictor and integrin-linked kinase can regulate 
AktS473 phosphorylation and cell survival in the absence of mTOR 
in a subset of human breast cancer cell lines (50). Although an 
mTORC2-independent function of Rictor in cell survival signaling 
cannot be completely ruled out from our studies, we show that 
the mTOR kinase inhibitor Torin-2 sensitizes wild-type but not 
Rictor−/− MEFs to UVB-induced apoptosis, supporting the hypoth-
esis that mTORC2 initiates pro-survival signaling in response to 
carcinogen treatment by activation of Akt-dependent pathways.
In summary, these studies show for the first time that, while 
dispensable for normal keratinocyte proliferation, mTORC2 is 
essential for both skin tumor development and maintenance of 
established tumors. They further suggest that mTORC2 controls 
pro-survival pathways both in vitro and in tumors. Although the 
development of mTORC2-specific inhibitors has been elusive, 
our results support the idea that activated Akt signaling will 
render specific tumor types more responsive to therapy target-
ing the mTOR pathway.
Supplementary Material
Supplementary Table 1, Figures 1 and 2 and scans of original gels 
used for Western analyses can be found at http://carcin.oxford-
journals.org/
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